¡Ya estamos en ! Descubre más
SLGCW

SomaLogic Warrant

Dejó de cotizar

SLGCW dejó de cotizar en bolsa el 5 de enero de 2024.

 

Acerca de: SomaLogic is a commercial-stage proteomics company. It operates as a protein biomarker discovery and clinical diagnostics company that develops slow off-rate modified aptamers, which are modified nucleic acid-based protein binding reagents that are specific for their cognate protein. The Somamers/SomaScan technology enables researchers to analyze various types of biological samples for protein biomarker signatures, which can be utilized in drug discovery and development.

Empleados: 451

Noticias

Positivo
Neutral
Negativo
Sentimiento 3 meses
Positivo 0%
Neutral 0%
Negativo 0%

No hemos recibido artículos de noticias recientes sobre SLGCW.

Gráficos de precios implementados con Lightweight Charts™